- IGC Pharma, Inc. recently obtained a patent for an innovative cannabinoid-based pain relief method.
- This method utilizes a unique blend of cannabinoids without psychoactive effects.
- The implication of this method and its potential application is poised to revolutionize the pharmaceutical industry.
Pharmaceutical breakthroughs are the catalysts for major revolutions in patient care, and they often redefine the landscape of treatment options. One such transformative development is the recently patented cannabinoid-based pain relief method by IGC Pharma, Inc. The company aims to redefine pain management by providing a healthier, non-psychoactive alternative to conventional analgesics.
Pain is a common health issue worldwide, severely impacting patients' quality of life. The primary treatment for moderate to severe pain has traditionally been opioid analgesics. However, the addictive nature and risk of overdose associated with these drugs have necessitated the search for alternative pain management methods. This is where cannabinoid-based treatments enter the picture.
IGC Pharma, Inc.'s pain-relief innovation centers on a unique blend of cannabinoids, specifically designed for transdermal absorption. The patent, European Patent No. 3193862, covers a cream or gel that interacts with the nervous and immune systems to provide effective pain relief. The standout feature is its non-psychoactive nature, meaning users will not experience the ‘high’ synonymous with some other cannabis-derived products.
Comments